NCT02579031View on ClinicalTrials.gov

A Comparison of an Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent for Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

NACompletedINTERVENTIONAL
Enrollment

1,300

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

April 30, 2019

Study Completion Date

May 31, 2020

Conditions
Coronary Artery DiseaseAcute Coronary Syndrome
Interventions
DEVICE

Orsiro

Novel biodegradable-polymer sirolimus-eluting stent used during primary percutaneous coronary intervention

DEVICE

Xience

Durable-polymer everolimus-eluting stent used during primary percutaneous coronary intervention

Trial Locations (10)

1011

Lausanne University Hospital, Lausanne

3010

Bern University Hospital, Dep. of Cardiology, Bern

Unknown

Kantonsspital Aarau, Aarau

Universitätsspital Basel, Basel

Universität Freiburg, Fribourg

HUG, Geneva

Kantonsspital Luzern, Lucerne

Kantonsspital St. Gallen, Sankt Gallen

Spital Wallis, Sion

Triemli, Zurich

All Listed Sponsors
collaborator

University of Lausanne Hospitals

OTHER

lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT02579031 - A Comparison of an Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent for Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention | Biotech Hunter | Biotech Hunter